Single Ascending Dose Tolerability Study of DG3173
Phase of Trial: Phase I
Latest Information Update: 22 Aug 2014
At a glance
- Drugs Veldoreotide (Primary)
- Indications Acromegaly; Carcinoid tumour; Diabetic retinopathy
- Focus Adverse reactions
- Sponsors Aspireo Pharmaceuticals
- 26 Feb 2009 Results reported in a DeveloGen media release.
- 17 Oct 2008 New trial record.
- 10 Oct 2008 Final results were expected in November 2008 according to a DeveloGen media release.